Holen Sie sich die Stockscreener-App
9.275
4.84%
0.415
Schlusskurs vom Vortag:
$8.86
Offen:
$9.08
24-Stunden-Volumen:
4.48M
Relative Volume:
0.94
Marktkapitalisierung:
$2.86B
Einnahmen:
$571.16M
Nettoeinkommen (Verlust:
$-38.10M
KGV:
-75.71
EPS:
-0.1225
Netto-Cashflow:
$-48.91M
1W Leistung:
+4.84%
1M Leistung:
+13.28%
6M Leistung:
+39.26%
1J Leistung:
-18.02%
1-Tages-Spanne:
$8.85
$9.64
1-Wochen-Bereich:
$8.62
$9.64
52-Wochen-Spanne:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.265 | 2.73B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.40 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.52 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.86 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
841.02 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.12 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Hochstufung | Needham | Hold → Buy |
| 2025-07-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Earnings call transcript: Amicus Therapeutics beats Q3 2025 earnings expectations - Investing.com
Amicus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Amicus Therapeutics Revenue Jump And Profit Turn Wall Street’s Head - Finimize
Amicus Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2025 - MarketScreener
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Q3 2025 Earnings: EPS of $0.06 Be - GuruFocus
Earnings Flash (FOLD) Amicus Therapeutics Inc. Posts Q3 Adjusted EPS $0.17 per Share, vs. FactSet Est of $0.06 - MarketScreener
Amicus Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Amicus Therapeutics Q3 2025 Financial Results and Corporate Updates - TradingView
Amicus Therapeutics Q3 revenue growth more than expected - MarketScreener
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates - Yahoo Finance
Institutional scanner results for Amicus Therapeutics Inc.Weekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Does Amicus Therapeutics Inc. stock trade at a discount to peersPortfolio Value Summary & Risk Managed Investment Signals - newser.com
Is Amicus Therapeutics Inc. trending in predictive chart modelsMarket Trend Report & Free Technical Confirmation Trade Alerts - newser.com
Amicus Therapeutics Q3 2025 Earnings Preview - MSN
Using RSI to spot recovery in Amicus Therapeutics Inc.2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com
How to manage a losing position in Amicus Therapeutics Inc.July 2025 Market Mood & Accurate Intraday Trade Tips - newser.com
Understanding Amicus Therapeutics Inc.’s price movementGold Moves & Reliable Entry Point Alerts - newser.com
What earnings revisions data tells us about Amicus Therapeutics Inc.July 2025 Trade Ideas & Daily Market Momentum Tracking - newser.com
Visual trend scoring systems applied to Amicus Therapeutics Inc.Trade Ideas & Intraday High Probability Setup Alerts - newser.com
Is Amicus Therapeutics Inc. meeting your algorithmic filter criteriaSwing Trade & Smart Investment Allocation Tips - newser.com
How interest rate cuts could boost Amicus Therapeutics Inc. stockJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Amicus Therapeutics Inc. (AM6) stock benefit from mergers2025 Volatility Report & Daily Oversold Bounce Ideas - newser.com
Is Amicus Therapeutics Inc. (AM6) stock nearing a technical breakoutCEO Change & Free AI Powered Buy and Sell Recommendations - newser.com
Why Amicus Therapeutics Inc. stock is a must watch in 2025Market Growth Summary & Weekly Top Gainers Trade List - newser.com
How Amicus Therapeutics Inc. (AM6) stock performs during market turbulencePortfolio Value Report & Risk Controlled Swing Alerts - newser.com
Chart based exit strategy for Amicus Therapeutics Inc.Market Sentiment Summary & Weekly Momentum Stock Picks - newser.com
Real time pattern detection on Amicus Therapeutics Inc. stock2025 Big Picture & Scalable Portfolio Growth Ideas - newser.com
Key resistance and support levels for Amicus Therapeutics Inc.2025 Top Decliners & Intraday High Probability Alerts - newser.com
What RSI levels show for Amicus Therapeutics Inc. (AM6) stock2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - Sahm
Using data models to predict Amicus Therapeutics Inc. stock movementJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Is Amicus Therapeutics Inc. (AM6) stock undervalued at current price2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Amicus Therapeutics, Inc. (FOLD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Is Amicus Therapeutics Inc. stock near bottom after decline2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - newser.com
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesEarnings Summary Report & AI Driven Price Predictions - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryEarnings Growth Summary & Technical Buy Zone Confirmations - newser.com
Amicus (Nasdaq: FOLD) to present at UBS and Jefferies investor conferences in Nov 2025 - Stock Titan
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.96%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):